Novel agonist of α₄β₂* neuronal nicotinic receptor with antinociceptive efficacy in rodent models of acute and chronic pain.

As shown in Figure 7 , relative to the no-drug control condition (121.3±12.0 movements/min, N=5), locomotor activity was not significantly reduced 1 (90.7±11.3 movements/min, N=5, P =0.10), 3 (89.8±8.1 movements/min, N=5, P =0.06), or 7 days (101.6±17.7 movements/min, N=5, P =0.37) after administration of Cris-104 (100 mg/kg), though locomotor activity at day 3 showed a nonsignificant trend toward inhibition.

also in 5,406 other papers